A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in r...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter M. Verheij
Citation Annals of Oncology (2016) 27 (2): 1-3. 10.1093/annonc/mdw237
Authors M. Verheij1, A. Cats1, P..M. Jansen Edwin1, C..T. van Grieken Nicole2, K. Aaronson Neil1, H. Boot1, A. Lind Pehr3, E. Meershoek – Klein Kranenbarg4, M. Nordsmark5, H. Putter4, H. van Tinteren1, J..H. Van De Velde Cornelis4
  • 1Netherlands Cancer Institute, Amsterdam, Netherlands, /
  • 2VU University Medical Center, Amsterdam, Netherlands, /
  • 3Karolinska University Hospital, Stockholm, Sweden, /
  • 4Leiden University Medical Center, Leiden, Netherlands, /
  • 5Åarhus University Hospital, Aarhus, Denmark, /


The mainstay of potentially curative treatment of gastric cancer is radical surgical resection. Because most patients in the Western world present with advanced stages long-term survival remains poor at about 25%, with local recurrences as part of treatment failure in up to 80% of cases. Evidence-based strategies aimed at improving outcome include adequate surgery, post-operative chemoradiotherapy (CRT) and peri-operative chemotherapy (CT). The current randomized phase III CRITICS-study (NCT00407186) investigated whether chemoradiotherapy after pre-operative chemotherapy and adequate (D2) surgery leads to improved overall survival (OS) in comparison with post-operative chemotherapy. Furthermore, toxicity of both treatment regimens was explored.